|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of antispasmodics in the treatment of irritable bowel syndrome显示文摘Irritable bowel syndrome(IBS)is a long-lasting,relapsing disorder characterized by abdominal pain/discomfort and altered bowel habits.Intestinal motility impairment and visceral hypersensitivity are the key factors among its multifactorial pathogenesis,both of which require effective treatment.Voltage-gated calcium channels mediate smooth muscle contraction and endocrine secretion and play important roles in neuronal transmission.Antispasmodics are a group of drugs that have been used in the treatment of IBS for decades.Alverine citrate,a spasmolytic,decreases the sensitivity of smooth muscle contractile proteins to calcium,and it is a selective 5-HT1A receptor antagonist.Alverine,in combination with simethicone,has been demonstrated to effectively reduce abdominal pain and discomfort in a large placebo-controlled trial.Mebeverine is a musculotropic agent that potently blocks intestinal peristalsis.Non-placebo-controlled trials have shown positive effects of mebeverine in IBS regarding symptom control;nevertheless,in recent placebo-controlled studies,mebeverine did not exhibit superiority over placebo.Otilonium bromide is poorly absorbed from the GI tract,where it acts locally as an L-type calcium channel blocker,an antimuscarinic and a tachykinin NK2receptor antagonist.Otilonium has effectively reduced pain and improved defecation alterations in placebocontrolled trials in IBS patients.Pinaverium bromide is also an L-type calcium channel blocker that acts locally in the GI tract.Pinaverium improves motility disorders and consequently reduces stool problems in IBS patients.Phloroglucinol and trimethylphloroglucinol are non-specific antispasmodics that reduced pain in IBS patients in a placebo-controlled trial.Antispasmodics have excellent safety profiles.T-type calcium channel blockers can abolish visceral hypersensitivity in animal models,which makes them potential candidates for the development of novel therapeutic agents in the treatment of IBS. | Anita Annaházi Richárd Róka András Rosztóczy Tibor Wittmann | 2014 | World Journal of Gastroenterology2014，20，20： | 15 |
| 2 | Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy显示文摘AIM:To assess the endoscopic activity before and after a one-year period of biological therapy and to evaluate the frequency of relapses and need for retreatment after stopping the biologicals in patients with Crohn’s disease(CD)and ulcerative colitis(UC).METHODS:The data from 41 patients with CD and 22 patients with UC were assessed.Twenty-four CD patients received infliximab,and 17 received adalimumab.The endoscopic severity of CD was quantified with the simplified endoscopic activity score for Crohn’s disease in CD and with the Mayo endoscopic subscore in UC.RESULTS:Mucosal healing was achieved in 23 CD and7 UC patients.Biological therapy had to be restarted in78%of patients achieving complete mucosal healing with CD and in 100%of patients with UC.Neither clinical remission nor mucosal healing was associated with the time to restarting the biological therapy in either CD or UC.CONCLUSION:Mucosal healing did not predict sustained clinical remission in patients in whom the biological therapies had been stopped. | Klaudia Farkas Péter László Lakatos Mónika Szcs va Pallagi-Kunstár Anita Bálint Ferenc Nagy Zoltán Szepes Noémi Vass Lajos S Kiss Tibor Wittmann Tamás Molnár | 2014 | World Journal of Gastroenterology2014，20，11： | 2 |
| 3 | Detailed esophageal function and morphological analysis shows high prevalence of gastroesophageal reflux disease and Barrett’s esophagus in patients with cervical inlet patch显示文摘 | A. Rosztóczy F. Izbéki I. B. Németh S. Dulic K. Vadászi R. Róka K. Gecse T. Gy?keres G. Lázár L. Tiszlavicz T. Wittmann | 2011 | Diseases of the Esophagus2011，，6： | 2 |
| 4 | Public policy modeling of distributed energy technologies : strategies, attributes, and challenges 显示文摘 | BRUCKNER T MORRISON R WITTMANN T | 2005 | Ecological Economics2005，54，23： | 1 |
| 5 | Approximation of fixed points of nonexpansive mappings显示文摘 | WITTMANN R | 1992 | Arch Math1992，58，： | 1 |
| 6 | Approximation of fixed points of nonexpansive mappings显示文摘 | Wittmann R | 1992 | Arch Math1992，58，5： | 1 |
| 7 | A preliminary study of longterm treatment with interferon gamma-lb and low-dose prednisolong in patients with idiopthic pulmonary fibrosis显示文摘 | Ziesche R Hofbauer E Wittmann K | 1999 | N Engl J Med1999，341，17： | 1 |
| 8 | Fermentative manufacture of succinic acid with Basfia succiniciproducens DD1 in serum flasks显示文摘 | Stellmacher R Hangebrauk J Wittmann C | | 0，，08： | 1 |
| 9 | Angew Chem Int Ed 显示文摘 | Wittmann S Schatz A Grass R N | 2010 | 49(10): 1867-18702010，49，10： | 1 |
| 10 | Approximation of fixed points of nonexpansive mappings显示文摘 | Wittmann R | 1992 | Arch Math1992，58，： | 1 |
| 11 | Approximation of fixed points of nonexpansive mappings显示文摘 | Wittmann R | 1992 | Arch Math1992，58，： | 1 |
| 12 | Microplates with integrated oxygen sensing for medium optimization in animal cell culture显示文摘 | Deshpande R R Wittmann C Heinzle E | 2004 | Cyotechnology2004，46，23： | 1 |
| 13 | Approximation of fixed points of nonexpansive mappings显示文摘 | WITTMANN R | 1992 | Arch Math1992，58，： | 1 |
| 14 | Approximation of fixed points of nonexpansive mapping显示文摘 | Wittmann R | 1992 | Arch Math1992，58，： | 1 |
| 15 | Approximation of fixed points of non-expansive mappings显示文摘 | WITTMANN R | 1992 | Arch Math1992，，58： | 1 |
| 16 | Altered protease signalling in the gut: a novel pathophysiological factor in irritable bowel syndrome 显示文摘 | Roka R Wittmann T Bueno L | 2008 | Neurogastroenterol Motil2008，20，8： | 1 |
| 17 | The anticatabolic effect of neuraxial blockade after hip surgery显示文摘 | Lattermann R Belohlavek G Wittmann S | 2005 | Anesth Analg2005，101，4： | 1 |
| 18 | Approximation of fixed points of nonexpansive mappings显示文摘 | Wittmann R | 1992 | Arch Math1992，59，： | 1 |
| 19 | A preliminary study of long-term treatment with interferon gamma-lb and low-dose prednisolone in patients with idiopathic pulmonaryfibrosis 显示文摘 | Ziesche R Hofbauer E Wittmann K etal | 1999 | N Engl J Med1999，341，17： | 1 |
| 20 | Trimless high precision ratioed resistors in D/A and A/D converters显示文摘 | Wittmann R Schardein W Hosticka B J | 1995 | IEEE J Sol Sta Circ1995，30，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员